Oscar Segurado

Oscar Segurado

Company: ASC Therapeutics

Job title: Chief Medical Officer


Executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and medical affairs.

Chief Medical Officer for ASC Therapeutics, formerly for Symvivo, Myriad Genetics-Crescendo and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira).

Senior medical leader experienced in matrixed, line management and consulting for biotechs, midsize and large pharma companies. Extensive expertise in gene therapy (ASC, AveXis, UCLA Ventures, UniQure, Symvivo), immuno-oncology (Amgen, AstraZeneca, Bellicum, Jazz), immuno-therapy (Bristol-Myers Squibb, Macrogenics, TriSalus), genomics (Freenome, Myriad) and protein/cell diagnostics (Abbott, BD, Crescendo), predominantly focused on oncology, hematology and autoimmunity, including personalized medicine, molecular and cellular biomarkers.

Holding a tenured Professorship of Immunology at the University of Leon, Spain, currently on leave. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain. Former associate professor at the Faculties of Medicine in the University of Munich, Germany, and University Complutense of Madrid, Spain.


Live Presenter Q&A 4:30 pm

Read more

day: Day One

Clinical Development of Advanced Gene Therapies for Hemophilia 3:50 pm

• Over the next 5-10 years the management and treatment of hemophilia will experience a revolution. A single intervention of gene therapy will become the treatment of choice for many patients • Standard gene therapy can achieve a permanent and successful amelioration of the bleeding episodes in adults with hemophilia, eliminating the need for prophylactic…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.